Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab in Chinese Participants with Advanced Solid Tumors
NCT03195478Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2017
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in solid tumor, sponsored by Bristol Myers Squibb. Started Aug 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03195478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03195478.